JAHA: Analysis of the efficacy of intensive fat-lowering therapy in patients with polyvascular diseases

Polyvascular atherosclerosis is associated with an increased risk of future cardiovascular events.
-enhanced fat-lowering therapy (ILT) can mitigate this risk.
recently, a study published in JAHA, an authoritative journal in the field of cardiovascular disease, explores the efficacy of ILT in patients with polyvascular disease and whether baseline LDL-C can determine its level of benefit.
researchers searched the electronic database until January 2020 to determine randomized controlled trials (e.g. statins, equinoxes, and PCSK9 (type 9 protein-converting enzyme oxalin) inhibitors for LDL-C subject therapy.
the main endpoint of the study was the main adverse vascular events.
the study included 7 studies in 94,362 patients (14,821 patients with polyvascular diseases, or 18.6%).
in patients with single vascular disease, ILT was associated with a 13% decrease in the primary endpoint (the ratio ratio was 0.87; 95% CI was 0.81-0.93 (P.0.0002) (absolute RR was 1.8%), The relative RR of patients with polyvascular disease was 15% (0.85; 95% CI was 0.80-0.90 (P<0.00001) (absolute RR was 6.5%) (interaction P=0.66).
, the relative benefits of ILT in patients with polyvascular disease are in LDL-C>100 mg/dL (RR 0.85; 95% CI is 0.80-0.90 (P<0.00 001)) is comparable to patients with LDL, it can be seen that patients with polyvascular disease and patients with single vascular disease can benefit from ILT equivalent.
in patients with polyvascular disease, the benefits of ILT do not depend on baseline LDL-C, which challenges the use of LDL-C as a prerequisite for initiating ILT.